14,905 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by L & S Advisors Inc

L & S Advisors Inc acquired a new position in Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 14,905 shares of the company’s stock, valued at approximately $2,584,000.

Other large investors also recently bought and sold shares of the company. International Assets Investment Management LLC raised its position in shares of Zoetis by 40.7% in the fourth quarter. International Assets Investment Management LLC now owns 2,429 shares of the company’s stock valued at $479,000 after buying an additional 703 shares during the last quarter. Aveo Capital Partners LLC purchased a new position in Zoetis in the 4th quarter worth approximately $225,000. Gryphon Financial Partners LLC boosted its holdings in shares of Zoetis by 11.8% during the 4th quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after purchasing an additional 322 shares during the last quarter. Jump Financial LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at approximately $339,000. Finally, Panagora Asset Management Inc. grew its position in shares of Zoetis by 1.1% in the fourth quarter. Panagora Asset Management Inc. now owns 10,717 shares of the company’s stock valued at $2,115,000 after purchasing an additional 118 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZTS. Stifel Nicolaus reissued a “buy” rating and set a $200.00 price objective on shares of Zoetis in a research note on Tuesday, August 27th. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, BTIG Research raised their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $217.11.

Zoetis Stock Performance

NYSE ZTS opened at $194.25 on Tuesday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The company has a market cap of $88.00 billion, a P/E ratio of 37.43, a P/E/G ratio of 2.92 and a beta of 0.88. The stock has a 50-day moving average of $183.22 and a two-hundred day moving average of $174.12. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the prior year, the firm earned $1.41 EPS. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.